{
  "docId": "019de076-b5af-740f-a5f5-cc716fe64761",
  "docSlug": "e5f34198aff4080f2687fe569caff4c0",
  "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
  "authorId": "neurosense-therapeutics",
  "authorName": "NeuroSense Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 33,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 24,
  "notes": "The slide shows baseline characteristics for a clinical trial, confirming that the treatment and placebo groups are well-matched.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/15",
  "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761",
  "deckJsonHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761.json",
  "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.18,
        "w": 0.12,
        "x": 0.86,
        "y": 0.02
      },
      "kind": "image",
      "text": "NeuroSense Therapeutics, Paradigm",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b9e5eadf-baee-407c-8897-156f1bf7e39a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.52,
        "x": 0.24,
        "y": 0.315
      },
      "kind": "table",
      "text": "Male, Female, Age, Height, Weight, BMI, TRICALS Risk Profile, Patients on background ALS therapy, ALSFRS-R at baseline, % Predicted SVC at baseline",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cb4d975b-2a38-41d7-a0b4-32c7db8ce666",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.5,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "PrimeC Phase 2b Study: Well Balanced Enrollment",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec1b1248-11ed-4b3f-9d63-6f3bb91806d1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "9fa0c0e6-51a3-40ce-8223-a907d77611e9",
      "evidence": "table/data: Male, Female, Age, Height, Weight, BMI, TRICALS Risk Profile, Patients on background ALS therapy, ALSFRS-R at baseline, % Predicted SVC at baseline",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 17,
      "from": 6,
      "beatId": "811b582e-32bd-4141-9a9d-a2d358e4ce91",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents PrimeC as a unique synergistic formulation with a powerful outcome, demonstrating statistically significant efficacy in key pre-clinical studies and promising results in Phase 2a and 2b clinical trials (p6-17).",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}